medigraphic.com
SPANISH

Revista Médica del Instituto Mexicano del Seguro Social

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2010, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2010; 48 (2)

Epilepsy and remission in primary care level

Estrada-Castillejos M, Soler-Huerta E, Gómez-Márquez M, Molar-Castro F, Sainz-Vázquez L, González-Contreras H
Full text How to cite this article

Language: Spanish
References: 12
Page: 189-192
PDF size: 25.95 Kb.


Key words:

epilepsy, nervous system diseases.

ABSTRACT

Objective: to identify the epilepsy remission period in a primary care unit.
Methods: there were 330 patients with diagnosis of epilepsy in remission according to the international criteria treated in a Primary Care Unit of the Instituto Mexicano del Seguro Social, Xalapa, Veracruz; There were 216 patients who were controlled (without epilepsy crisis) 150 of them were interviewed with a structure instrument designed for this purpose.
Results: the history of epilepsy was from five to nine years (49 %). Partial crisis was identified in 54 %. The age of diagnosis was established in 44% between one to ten years. The patients received drug treatment during a period of three to eight years in 51 % of them. The monotherapy was used in 51 % of the cases.
Conclusions: remission of epilepsy crisis can be obtained in most patients with two years drug treatment. However, we can not talk about definitive cure.


REFERENCES

  1. Carrizosa MJ, Cornejo OW. Epilepsia curada y controlada. Rev Mex Neuroci 2004;5(4):319-324.

  2. Reséndiz AJ, Rodríguez RE, Contreras BJ, Ceja MH, Barragán PE, Garza MS, et al. Estudio abierto aleatorio y comparativo de la monoterapia con topiramato frente a carbamazepina en el tratamiento de pacientes pediátricos con epilepsia de reciente diagnóstico. Rev Neurol 2004;39(3): 201-204.

  3. Corredera GE, Gómez AJ, Arias M, Seijo MM, Rodríguez J, Rubio NE, López F. Tratamiento com topiramato em pacientes com epilepsia refractaria. Ver Neurol 2003;37(5):401-404.

  4. Hauser A. Prognosis of epilepsy; the Rochester studies. En: Jallon P, editor. Prognosis of epilepsies. Paris: John Lebbey Eutotext; 2003. p. 55-63.

  5. Linsten H, Stenlund H, Forsgren L. Remission of seizures in a population based adult cohort with a newly diagnosed unprovoked epileptic seizure. Epilepsia 2001;42(8):1025-1030.

  6. Ramos LJ, Cansinello GE, Vázquez LM, Carrasco MML, Muñoz HA, Martín GM. Remisión a largo plazo de la epilepsia en la infancia estudio prospectivo. Rev Neurol 2002;34(9):824-829.

  7. Santiago RE, Sales CV, Ramos RR. Factores de riesgo para incumplimiento terapéutico en pacientes con epilepsias. Gac Med Mex 2002;139 (3):241-246.

  8. Arroyo S. Evaluación de la epilepsia farmacorresistente. Rev Neurol 2000;30(9):881-886.

  9. Sancho RJ, López T. Pronóstico de las epilepsias. Rev Neurol 2000;30(4):333-336.

  10. Castro-Sánchez A. El apoyo social en la enfermedad crónica: el caso de los pacientes diabéticos tipo 2. Rev Salud Publica Nutr 2006;7(4).

  11. Pérez PJ, Sosa AM, González CS. Conocimiento, control clínico y actitudes de los médicos de atención primaria frente a los pacientes epilépticos. Rev Neurol 2005;40(7):385-393.

  12. Argumosa A, Herranz JL. El coste económico de la epilepsia infantil en España. Rev Neurol 2000;30(2):104-108.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Med Inst Mex Seguro Soc. 2010;48